Analyst Viewpoint
Growth in incidence of helminth infections worldwide is a key factor driving the anthelmintic drugs market revenue. These drugs help expel helminths (parasitic worms) and other internal parasites from the human or animal body without causing any major harm to the host.
Increase in frequency of compound screening with parasites is expediting the discovery of anthelmintic drugs.
Anthelmintic drugs market manufacturers are using plant materials with more than 90% of egg hatching inhibitory effects as anthelmintic agents, thereby offering dose-dependent anthelmintic activities.
Key players are following the latest anthelmintic drugs market trends and introducing clinically appropriate, safe, and cost-effective anthelmintic drugs that help achieve optimal therapeutic outcomes.
Anthelmintic drugs, also known as anthelmintics, are designed to fight infections caused due to parasites. These parasites, called helminths, can infect lungs, intestines, or body tissues of human beings or animals.
Anthelmintics work either by disturbing the metabolic processes of parasites or killing them. In both the methods, the ultimate objective is to drive them away from the body.
In January 2023, the WHO published an article that stated that soil-transmitted helminth (STH) infections affect more than 24% of the global population. It further stated that such infections target the impoverished and most vulnerable communities that have limited access to hygiene, sanitation, and safe water.
Rise in need for anthelmintic drugs to combat these infections is augmenting the anti-parasitic medications market.
Anthelmintics drugs are being used in various mass deworming campaigns for school-going children in several under-developed economies. They are also used for livestock mass deworming.
Thus, the deworming drugs market is expanding at a steady pace across the globe, with albendazole and mebendazole prescribed for soil-transmitted helminths, and praziquantel for tapeworms and schistosomiasis.
Veterinary anthelmintic drugs market dynamics are governed by anthelmintic drugs that are prescribed for off-label usage in veterinary medicine.
Pyrantel pamoate (brand names Nemex and Nemex 2) is one such dewormer prescribed off-label for the treatment of intestinal roundworm, stomach worm, and hookworm parasites in cats, dogs, birds, rodents, and rabbits.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Helminths such as trematodes, nematodes, and cestodes are a global threat worldwide, as existing medications such as diethylcarbamazine, benzimidazoles, praziquantel, and ivermectin are at the risk of developing resistance, thereby halting the progress regarding keeping helminth infections in control.
One of the goals of the WHO is to eliminate or control these tropical ailments. As per Pan American Health Organization (PAHO), countries accounting for maximum helminth infections include Colombia, Brazil, Mexico, Guatemala, Bolivia, Honduras, Haiti, Peru, Nicaragua, and the Dominican Republic.
High incidence of helminth infections in these countries can be ascribed to the lack of adequate sanitation facilities such as unkempt septic tanks and ventilated pit latrines.
Research states that one gram of nightsoil from an infected person is likely to contain close to 100 parasite eggs. This is fueling the anthelmintic drugs market growth.
The WHO/PAHO has recommended interventions such as mass administration of mebendazole (500 mg) or albendazole (400 mg) to those at a higher risk of STH infection such as pre-schoolers, school-going children, women of childbearing age, pregnant women, and lactating mothers due to the high incidence of helminth infections across the globe.
The WHO encourages the sharing of resources and data regarding research findings related to anthelmintic drugs in order to exercise mass control over helminth infections. For instance, open sources, including genomic information from several parasites, have facilitated identification of targets for novel anti-parasitic agents.
Phenotyping screening and compound screening are recommended to enable screening in various assays against several diverse parasitic pathogens. Out of these compounds that have been identified, tolfenpyrad, a repurposed insecticide, has been successful in creating more selective and potent derivatives.
Lymphatic filariasis (LF) treatment was one such initiative undertaken by the WHO in 2000. It resulted in the elimination of LF as a public health problem in 14 countries.
Thus, ongoing discoveries pertaining to anthelmintic drugs are augmenting the global anthelmintic drugs market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the recent anthelmintic drugs market insights, North America accounted for the largest share of the global landscape in 2022. The region is expected to maintain its dominance during the forecast period.
The U.S. is one of the top anthelmintic drugs manufacturers worldwide. Growth in pharmaceuticals-related infrastructure in the country is generating lucrative anthelmintic drugs business opportunities for companies operating in the sector in North America.
Asia Pacific, Latin America, and Middle East & Africa also constitute vital anthelmintic drugs market share due to the vast presence of low-income groups who are prone to helminth infections in the wake of inadequate sanitation facilities.
The WHO and PAHO are collaborating with key players in the anthelmintic drugs industry to mass manufacture anthelmintic drugs in order to serve the under-developed economies of Latin America, Middle East & Africa, and Asia Pacific. For instance, albendazole and mebendazole are mass produced to be administered in these regions.
Leading market players are also incorporating nemacol, a small molecule inhibitor of C. elegans vesicular acetylcholine transporter with anthelmintic potential, into their offerings of anthelmintic drugs.
Anthelmintic drugs market report scope covers prominent players such as Novartis AG, Zoetis, Inc., Amneal Pharmaceuticals, Inc., Cipla Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Bayer AG, Merck & Co. Inc. (Intervet Inc.), and Boehringer Ingelheim International GmbH.
These companies have been summarized in the market report in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 2.6 Bn |
| Market Forecast (Value) in 2031 | US$ 3.7 Bn |
| Growth Rate (CAGR) | 3.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 2.6 Bn in 2022
It is projected to grow at a CAGR of 3.9% from 2023 to 2031
Growth in incidence of helminth infection and extensive research in anthelmintic medications
The hospital pharmacies segment accounted for the largest share in 2022
North America was the dominant region in 2022
Novartis AG, Zoetis, Inc., Amneal Pharmaceuticals, Inc., Cipla Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Bayer AG, Merck & Co. Inc. (Intervet Inc.), and Boehringer Ingelheim International GmbH
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anthelmintic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anthelmintic Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Anthelmintic Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Benzimidazole
6.3.2. Piperazine
6.3.3. Others
6.4. Market Attractiveness, by Drug Class
7. Global Anthelmintic Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.4. Market Attractiveness, by Route of Administration
8. Global Anthelmintic Drugs Market Analysis and Forecast, By Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Application, 2017–2031
8.3.1. Human
8.3.1.1. Parenchymal Neurocysticercosis
8.3.1.2. Gastrointestinal Infections
8.3.2. Animal
8.4. Market Attractiveness, By Application
9. Global Anthelmintic Drugs Market Analysis and Forecast, by Target Pathogen
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Target Pathogen, 2017–2031
9.3.1. Ascaris Lumbricoides (Roundworm)
9.3.2. Trichuris Trichiura (Whipworm)
9.3.3. Enterobius Vermicularis (Pinworm)
9.3.4. Ancylostoma Duodenale (Hookworm)
9.3.5. Others
9.4. Market Attractiveness, by Target Pathogen
10. Global Anthelmintic Drugs Market Analysis and Forecast, by Distribution Channel
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Veterinary Pharmacies
10.3.5. Veterinary Hospitals & Clinics
10.4. Market Attractiveness, by Distribution Channel
11. Global Anthelmintic Drugs Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Anthelmintic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Benzimidazole
12.2.2. Piperazine
12.2.3. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Injectable
12.5. Market Attractiveness, by Route of Administration
12.6. Market Value Forecast, By Application, 2017–2031
12.6.1. Human
12.6.1.1. Parenchymal Neurocysticercosis
12.6.1.2. Gastrointestinal Infections
12.6.2. Animal
12.7. Market Attractiveness, By Application
12.8. Market Value Forecast, by Target Pathogen, 2017–2031
12.8.1. Ascaris Lumbricoides (Roundworm)
12.8.2. Trichuris Trichiura (Whipworm)
12.8.3. Enterobius Vermicularis (Pinworm)
12.8.4. Ancylostoma Duodenale (Hookworm)
12.8.5. Others
12.9. Market Attractiveness, by Target Pathogen
12.10. Market Value Forecast, by Distribution Channel, 2017–2031
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.10.4. Veterinary Pharmacies
12.10.5. Veterinary Hospitals & Clinics
12.11. Market Attractiveness, by Distribution Channel
12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Drug Class
12.13.2. By Route of Administration
12.13.3. By Application
12.13.4. By Target Pathogen
12.13.5. By Distribution Channel
12.13.6. By Country
13. Europe Anthelmintic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Benzimidazole
13.2.2. Piperazine
13.2.3. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Injectable
13.5. Market Attractiveness, by Route of Administration
13.6. Market Value Forecast, By Application, 2017–2031
13.6.1. Human
13.6.1.1. Parenchymal Neurocysticercosis
13.6.1.2. Gastrointestinal Infections
13.6.2. Animal
13.7. Market Attractiveness, By Application
13.8. Market Value Forecast, by Target Pathogen, 2017–2031
13.8.1. Ascaris Lumbricoides (Roundworm)
13.8.2. Trichuris Trichiura (Whipworm)
13.8.3. Enterobius Vermicularis (Pinworm)
13.8.4. Ancylostoma Duodenale (Hookworm)
13.8.5. Others
13.9. Market Attractiveness, by Target Pathogen
13.10. Market Value Forecast, by Distribution Channel, 2017–2031
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.10.4. Veterinary Pharmacies
13.10.5. Veterinary Hospitals & Clinics
13.11. Market Attractiveness, by Distribution Channel
13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Drug Class
13.13.2. By Route of Administration
13.13.3. By Application
13.13.4. By Target Pathogen
13.13.5. By Distribution Channel
13.13.6. By Country/Sub-region
14. Asia Pacific Anthelmintic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Benzimidazole
14.2.2. Piperazine
14.2.3. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Injectable
14.5. Market Attractiveness, by Route of Administration
14.6. Market Value Forecast, By Application, 2017–2031
14.6.1. Human
14.6.1.1. Parenchymal Neurocysticercosis
14.6.1.2. Gastrointestinal Infections
14.6.2. Animal
14.7. Market Attractiveness, By Application
14.8. Market Value Forecast, by Target Pathogen, 2017–2031
14.8.1. Ascaris Lumbricoides (Roundworm)
14.8.2. Trichuris Trichiura (Whipworm)
14.8.3. Enterobius Vermicularis (Pinworm)
14.8.4. Ancylostoma Duodenale (Hookworm)
14.8.5. Others
14.9. Market Attractiveness, by Target Pathogen
14.10. Market Value Forecast, by Distribution Channel, 2017–2031
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.10.4. Veterinary Pharmacies
14.10.5. Veterinary Hospitals & Clinics
14.11. Market Attractiveness, by Distribution Channel
14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Drug Class
14.13.2. By Route of Administration
14.13.3. By Application
14.13.4. By Target Pathogen
14.13.5. By Distribution Channel
14.13.6. By Country/Sub-region
15. Latin America Anthelmintic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017–2031
15.2.1. Benzimidazole
15.2.2. Piperazine
15.2.3. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Injectable
15.5. Market Attractiveness, by Route of Administration
15.6. Market Value Forecast, By Application, 2017–2031
15.6.1. Human
15.6.1.1. Parenchymal Neurocysticercosis
15.6.1.2. Gastrointestinal Infections
15.6.2. Animal
15.7. Market Attractiveness, By Application
15.8. Market Value Forecast, by Target Pathogen, 2017–2031
15.8.1. Ascaris Lumbricoides (Roundworm)
15.8.2. Trichuris Trichiura (Whipworm)
15.8.3. Enterobius Vermicularis (Pinworm)
15.8.4. Ancylostoma Duodenale (Hookworm)
15.8.5. Others
15.9. Market Attractiveness, by Target Pathogen
15.10. Market Value Forecast, by Distribution Channel, 2017–2031
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Online Pharmacies
15.10.4. Veterinary Pharmacies
15.10.5. Veterinary Hospitals & Clinics
15.11. Market Attractiveness, by Distribution Channel
15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Drug Class
15.13.2. By Route of Administration
15.13.3. By Application
15.13.4. By Target Pathogen
15.13.5. By Distribution Channel
15.13.6. By Country/Sub-region
16. Middle East & Africa Anthelmintic Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Class, 2017–2031
16.2.1. Benzimidazole
16.2.2. Piperazine
16.2.3. Others
16.3. Market Attractiveness, by Drug Class
16.4. Market Value Forecast, by Route of Administration, 2017–2031
16.4.1. Oral
16.4.2. Injectable
16.5. Market Attractiveness, by Route of Administration
16.6. Market Value Forecast, By Application, 2017–2031
16.6.1. Human
16.6.1.1. Parenchymal Neurocysticercosis
16.6.1.2. Gastrointestinal Infections
16.6.2. Animal
16.7. Market Attractiveness, By Application
16.8. Market Value Forecast, by Target Pathogen, 2017–2031
16.8.1. Ascaris Lumbricoides (Roundworm)
16.8.2. Trichuris Trichiura (Whipworm)
16.8.3. Enterobius Vermicularis (Pinworm)
16.8.4. Ancylostoma Duodenale (Hookworm)
16.8.5. Others
16.9. Market Attractiveness, by Target Pathogen
16.10. Market Value Forecast, by Distribution Channel, 2017–2031
16.10.1. Hospital Pharmacies
16.10.2. Retail Pharmacies
16.10.3. Online Pharmacies
16.10.4. Veterinary Pharmacies
16.10.5. Veterinary Hospitals & Clinics
16.11. Market Attractiveness, by Distribution Channel
16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Drug Class
16.13.2. By Route of Administration
16.13.3. By Application
16.13.4. By Target Pathogen
16.13.5. By Distribution Channel
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. Novartis AG
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Zoetis, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Amneal Pharmaceuticals, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Cipla Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Sun Pharmaceutical Industries Ltd.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. GlaxoSmithKline plc
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Bayer AG
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Merck & Co. Inc. (Intervet Inc.)
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Boehringer Ingelheim International GmbH
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
List of Tables
Table 01: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031
Table 04: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031
Table 05: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 09: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 10: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031
Table 11: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031
Table 12: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031
Table 17: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031
Table 18: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 19: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 21: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 22: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031
Table 23: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031
Table 24: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 27: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 28: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031
Table 29: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031
Table 30: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 31: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 33: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 34: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031
Table 35: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031
Table 36: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Anthelmintic Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Anthelmintic Drugs Market Value Share, by Drug Class, 2022
Figure 04: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 05: Global Anthelmintic Drugs Market Value Share, by Route of Administration, 2022
Figure 06: Global Anthelmintic Drugs Market Revenue (US$ Mn), By Application, 2022
Figure 07: Global Anthelmintic Drugs Market Value Share, By Application, 2022
Figure 08: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Target Pathogen, 2022
Figure 09: Global Anthelmintic Drugs Market Value Share, by Target Pathogen, 2022
Figure 10: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 11: Global Anthelmintic Drugs Market Value Share, by Distribution Channel, 2022
Figure 12: Global Anthelmintic Drugs Market Value Share, by Region, 2022
Figure 13: Global Anthelmintic Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 14: Global Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 15: Global Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 16: Global Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 17: Global Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 18: Global Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031
Figure 19: Global Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031
Figure 20: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Target Pathogen, 2022
Figure 21: Global Anthelmintic Drugs Market Value Share, by Target Pathogen, 2022
Figure 22: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 23: Global Anthelmintic Drugs Market Value Share, by Distribution Channel, 2022
Figure 24: Global Anthelmintic Drugs Market Value Share Analysis, by Region, 2022–2031
Figure 25: Global Anthelmintic Drugs Market Attractiveness Analysis, by Region, 2023–2031
Figure 26: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 27: North America Anthelmintic Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 28: North America Anthelmintic Drugs Market Value Share Analysis, by Country, 2022–2031
Figure 29: North America Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 30: North America Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 31: North America Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031
Figure 32: North America Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031
Figure 33: North America Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 34: North America Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 35: North America Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 36: North America Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031
Figure 37: North America Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031
Figure 38: North America Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 39: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 40: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 41: Europe Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 42: Europe Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 43: Europe Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 44: Europe Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031
Figure 45: Europe Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031
Figure 46: Europe Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 47: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 48: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 49: Europe Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031
Figure 50: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031
Figure 51: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 52: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 53: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 54: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 55: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 56: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 57: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031
Figure 58: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031
Figure 59: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 60: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 61: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 62: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031
Figure 63: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031
Figure 64: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 65: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 66: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 67: Latin America Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 68: Latin America Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 69: Latin America Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 70: Latin America Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031
Figure 71: Latin America Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031
Figure 72: Latin America Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 73: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 74: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 75: Latin America Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031
Figure 76: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031
Figure 77: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 78: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 79: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 80: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 81: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 82: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 83: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031
Figure 84: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031
Figure 85: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 86: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 87: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 88: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031
Figure 89: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031
Figure 90: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Anthelmintic Drugs Market
